Structure and function of inositol triphosphate receptors
肌醇三磷酸受体的结构和功能
基本信息
- 批准号:10365669
- 负责人:
- 金额:$ 32.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-10 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AffinityAgonistApoptosisArchitectureAutoimmune DiseasesBindingBinding SitesBiochemicalBiological AssayBiophysicsCalciumCalcium SignalingCell divisionCoupledCryoelectron MicroscopyDataDevelopmentDiseaseDistantElectrophysiology (science)Endoplasmic ReticulumFluorescenceGene ExpressionGoalsGrowth FactorHormonesHumanITPR1 geneImageInositolIon Channel GatingLeadLearningLigandsLiposomesMalignant NeoplasmsMediatingMembraneMemoryMetabolicMetabolic DiseasesMitochondriaMolecularMolecular ConformationNeurodegenerative DisordersNeurotransmittersPathogenesisPathologicPeptidesPharmacologyPhysiologicalPhysiological ProcessesPositioning AttributePropertyPublishingReceptor InhibitionRegulationResearchResolutionRoleSignal TransductionSiteStructureSynaptic TransmissionTestingTherapeutic AgentsX-Ray Crystallographybasecell motilitycell typedesensitizationinsightmutantnovelnovel therapeutic interventionnovel therapeuticspatch clamppositive allosteric modulatorprogramsprotein aminoacid sequencereceptorrelease of sequestered calcium ion into cytoplasmsmall moleculetooltraffickingtripolyphosphate
项目摘要
PROJECT SUMMARY
Inositol 1,4,5-triphosphate receptors (IP3Rs) integrate diverse signals generated by hormones, growth
factors, neurotransmitters, and changes in metabolic state to modulate downstream signaling in all cell types.
IP3Rs are ligand-gated ion channels that are further regulated by allosteric and covalent mechanisms,
mediating Ca2+ release from the endoplasmic reticulum (ER). The resulting increases of cytoplasmic and
mitochondrial Ca2+ concentrations regulate many physiological processes (e.g., learning, memory, membrane
trafficking, synaptic transmission, secretion, motility, membrane excitability, gene expression, cell division, and
apoptosis). Furthermore, pathological dysregulation of IP3Rs and calcium signaling is implicated in cancer,
neurodegenerative, autoimmune, and metabolic diseases, making IP3Rs promising targets for treatment of
these diseases. Despite recent advances in structural studies, fundamental questions regarding the
mechanisms of ligand interactions and channel gating remain mostly unanswered, in part because of the large
size and complexity of IP3Rs and the limited availability of specific pharmacological tools.
In this proposal, we will (Aim 1) combine cryo-electron microscopy (cryo-EM) and X-ray crystallography
in conjunction with functional IP3R assays based on fluorescence-based calcium imaging to elucidate the
general themes of IP3R gating cycle and molecular basis for receptor inhibition by small molecules.
Our recently published data revealed that the IP3 binding site is occupied by a loop that we have termed
the self-binding peptide (SBP), which is located distantly in the primary sequence. We hypothesize that the
SBP is a novel regulatory site in IP3Rs that can modulate the apparent affinity for IP3, and thereby Ca2+
channel activity, and that the divergence of SBP sequences between IP3R subtypes contributes to their distinct
regulatory properties. We will perform (Aim 2) functional and structural studies on IP3R subtypes and SBP
mutants to test this hypothesis and identify the structural determinants of this interaction.
Completion of these aims will yield unparalleled mechanistic insight into IP3R gating and regulation,
potentially leading to the development of novel and specific pharmacological modulators of IP3Rs. In addition
to being used as a long-sought research tools to study IP3Rs, these compounds will serve as a starting point
for development of novel therapeutic approaches to treat diseases associated with aberrant IP3R activity.
项目总结
1,4,5-三磷酸肌醇受体(IP3Rs)整合了激素、生长发育等多种信号。
因子、神经递质和代谢状态的变化来调节所有细胞类型中的下游信号。
IP3R是受变构和共价机制进一步调节的配体门控离子通道,
介导内质网(ER)的钙释放。由此产生的细胞质和
线粒体钙离子浓度调节许多生理过程(例如,学习、记忆、膜
运输、突触传递、分泌、运动性、膜兴奋性、基因表达、细胞分裂和
细胞凋亡)。此外,IP3Rs和钙信号的病理性失调与癌症有关,
神经退行性疾病、自身免疫疾病和代谢性疾病,使IP3Rs成为治疗
这些疾病。尽管最近在结构研究方面取得了进展,但关于
配体相互作用和通道门控的机制大多仍未得到解答,部分原因是
IP3R的规模和复杂性以及特定药理工具的可获得性有限。
在这个提案中,我们将(目标1)结合低温电子显微镜(Cryo-EM)和X射线结晶学
结合基于荧光的钙成像的功能IP3R分析来阐明
IP3R门控循环的一般主题和小分子抑制受体的分子基础。
我们最近公布的数据显示,IP3结合位点被我们称为
自结合多肽(SBP),位于初级序列的远端。我们假设
SBP是IP3Rs中的一个新的调控位点,可以调节对IP3的表观亲和力,从而调节钙离子
通道活动,以及IP3R亚型之间SBP序列的差异有助于其不同的
监管属性。我们将对IP3R亚型和SBP进行(目标2)功能和结构研究
突变体来检验这一假说,并确定这种相互作用的结构决定因素。
完成这些目标将产生对IP3R门槛和监管的无与伦比的机械性洞察,
潜在地导致了IP3Rs新的和特定的药理调节剂的开发。此外
这些化合物将作为人们长期寻求的研究工具来研究IP3R,将作为一个起点
用于开发新的治疗方法来治疗与IP3R活性异常相关的疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ERKAN KARAKAS其他文献
ERKAN KARAKAS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ERKAN KARAKAS', 18)}}的其他基金
Structure and function of inositol triphosphate receptors
肌醇三磷酸受体的结构和功能
- 批准号:
10645116 - 财政年份:2021
- 资助金额:
$ 32.78万 - 项目类别:
Structure and function of inositol triphosphate receptors
肌醇三磷酸受体的结构和功能
- 批准号:
10580508 - 财政年份:2021
- 资助金额:
$ 32.78万 - 项目类别:
Structure and function of inositol triphosphate receptors
肌醇三磷酸受体的结构和功能
- 批准号:
10482419 - 财政年份:2021
- 资助金额:
$ 32.78万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 32.78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 32.78万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 32.78万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 32.78万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 32.78万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 32.78万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 32.78万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 32.78万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 32.78万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 32.78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)